Remarkable new research by a University of Virginia undergraduate may help explain recurrent Crohn’s disease in children and open the door to new ways to treat or even cure the devastating condition.
AstraZeneca posts 16% drop in Q3 2023 profit after tax
AstraZeneca’s earnings per share (EPS) on a reported basis dropped by 16% to $0.89 from $1.06 in Q3 2022. Credit: Ascannio / Shutterstock.com. AstraZeneca has